Skip to main content
. Author manuscript; available in PMC: 2012 Aug 27.
Published in final edited form as: Clin Cancer Res. 2008 Jul 1;14(13):4284–4291. doi: 10.1158/1078-0432.CCR-07-5226

Figure 4. The effect of increasing doses of AZD0530 on expression and activation of c-Src and FAK in HNSCC cell lines.

Figure 4

Figure 4

(A) UM-22B, 1483 and PCI-37B cells were treated with AZD0530 (1–104 nM) or DMSO for 2 hours prior to lysis. Immunoblotting was performed with pY418 c-Src antibody, anti-c-Src antibody, pFAK Tyr 861 and total FAK. (B) Cal-33 cells were treated with increasing concentrations of AZD0530 (0.06–6µM) or DMSO for 2 hrs followed by immunoblotting for total and activated c-Src, E-cadherin and pFAK Y861. The experiment was performed 3 times with similar results.